Barnett & Company’s Moderna MRNA Stock Holding History

Barnett & Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150	Closed	-$38K	–	198
2021 Q4	$38K	Buy	+150	New	+$43.9K	0.03%	148

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barnett & Company's MRNA Position: Q1 2022 in Review

Barnett & Company sold out of Moderna (MRNA) in Q1 2022, closing a stake of 150 shares — an estimated $38K sold.

Barnett & Company first reported a position in MRNA in Q4 2021 and held it in 1 quarter. The position peaked at $38K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Barnett & Company reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Barnett & Company sold 150 Moderna shares in Q1 2022, an estimated $38K.
Barnett & Company first reported a position in Moderna in Q4 2021 and held it in 1 quarter.
Barnett & Company's Moderna position peaked at $38K in Q4 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Barnett & Company's 13F filing for Q1 2022, filed 28 Apr 2022.